Urogen Pharma Ltd (NASDAQ:URGN) has been given a consensus rating of “Buy” by the ten brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $65.25.

A number of research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Urogen Pharma in a research note on Thursday, September 13th. They issued a “buy” rating and a $70.00 price target on the stock. Oppenheimer set a $75.00 price target on Urogen Pharma and gave the company a “buy” rating in a research note on Tuesday, August 14th. Finally, Cowen reissued a “buy” rating on shares of Urogen Pharma in a research note on Tuesday, August 14th.

URGN traded up $2.99 during mid-day trading on Friday, reaching $44.76. The stock had a trading volume of 72,812 shares, compared to its average volume of 109,403. The firm has a market capitalization of $649.48 million, a price-to-earnings ratio of -20.92 and a beta of 2.08. Urogen Pharma has a 52 week low of $25.56 and a 52 week high of $69.57.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.25). The firm had revenue of $0.36 million during the quarter. Urogen Pharma had a negative net margin of 470.54% and a negative return on equity of 44.24%. On average, equities analysts forecast that Urogen Pharma will post -4.12 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of URGN. Menora Mivtachim Holdings LTD. lifted its stake in shares of Urogen Pharma by 35.5% in the 1st quarter. Menora Mivtachim Holdings LTD. now owns 2,045,629 shares of the company’s stock valued at $101,647,000 after purchasing an additional 535,622 shares during the period. Citadel Advisors LLC lifted its stake in shares of Urogen Pharma by 294.6% in the 2nd quarter. Citadel Advisors LLC now owns 321,034 shares of the company’s stock valued at $15,974,000 after purchasing an additional 239,676 shares during the period. Millennium Management LLC lifted its stake in shares of Urogen Pharma by 1,285.4% in the 1st quarter. Millennium Management LLC now owns 159,113 shares of the company’s stock valued at $7,906,000 after purchasing an additional 147,628 shares during the period. BlackRock Inc. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $4,468,000. Finally, Bainco International Investors lifted its stake in shares of Urogen Pharma by 67.2% in the 2nd quarter. Bainco International Investors now owns 175,461 shares of the company’s stock valued at $8,731,000 after purchasing an additional 70,500 shares during the period. 71.11% of the stock is currently owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.